Yue-Yun Lai
Overview
Explore the profile of Yue-Yun Lai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
481
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhu H, Liu Y, Jia J, Qin Y, Zhao X, Lai Y
Blood
. 2018 May;
131(26):2987-2989.
PMID: 29728404
No abstract available.
12.
Zhao H, Song Y, Cao X, Qin Y, Lai Y, Jiang H, et al.
Ann Hematol
. 2018 Feb;
97(5):799-811.
PMID: 29429020
Relapse remains one of the major obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (PhALL) even after allogeneic hematopoietic stem cell transplantation. The persistence of leukemia-propagating cells (LPCs) may lead to...
13.
Qin Y, Zhao T, Zhu H, Wang J, Jia J, Lai Y, et al.
Med Sci Monit
. 2018 Feb;
24:758-767.
PMID: 29408852
BACKGROUND Acute myeloid leukemia with intermediate cytogenetic risk (ICR-AML) needs to be stratified. The abnormal gene expression might be prognostic, and its cutoff value for patient grouping is pivotal. MATERIAL...
14.
Kong Y, Cao X, Zhang X, Shi M, Lai Y, Wang Y, et al.
Blood
. 2017 Dec;
131(11):1219-1233.
PMID: 29288170
The pathogenesis of corticosteroid-resistant immune thrombocytopenia (ITP), a clinically challenging condition in which patients exhibit either no response to corticosteroids or are corticosteroid-dependent, remains poorly understood. Murine studies suggest that...
15.
Du X, Lai Y, Xiao Z, Liu T, Hu Y, Sun A, et al.
Asia Pac J Clin Oncol
. 2017 Dec;
14(3):270-278.
PMID: 29282890
Background: Azacitidine safety and efficacy were established in studies of mainly Caucasian patients. Differences in drug metabolism enzymes between Caucasian and East Asian populations prevent extrapolation of drug effects between...
16.
Kong Y, Wu Y, Song Y, Shi M, Cao X, Zhao H, et al.
J Transl Med
. 2017 Sep;
15(1):184.
PMID: 28854975
Background: As one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (PhALL), relapse of PhALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a...
17.
Chen H, Liu K, Xu L, Chen Y, Zhang X, Wang Y, et al.
Leuk Res
. 2017 Jun;
59:136-141.
PMID: 28654842
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an important curative option for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have a poor response to chemotherapy plus imatinib....
18.
Gao L, Liu Q, Shi Y, Dang H, He Q, Wang Z, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
. 2017 Jun;
25(3):807-812.
PMID: 28641640
Objective: To investigate the efficiency of direct fluorescence in situ hybridization (D-FISH) versus FISH on CD138 immunomagnetic sorting myeloma cells (MACS-FISH) to detect the cytogenetic abnormalities of multiple myeloma. Methods:...
19.
Wang S, Wang P, Gale R, Qin Y, Liu Y, Lai Y, et al.
Oncotarget
. 2017 Apr;
8(22):35984-36000.
PMID: 28415593
Relapse is the major cause of treatment-failure in adults with B-cell acute lymphoblastic leukemia (ALL) achieving complete remission after induction chemotherapy. Greater precision identifying persons likely to relapse is important....
20.
Qin Y, Jiang Q, Lai Y, Jiang H, Shi H, Zhao X, et al.
Leuk Lymphoma
. 2016 Oct;
58(6):1384-1393.
PMID: 27733081
To investigate the impact of the combination of early molecular and cytogenetic responses on the achievement of MR4.5, 228 newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib...